Artia Global Partners’s NewAmsterdam Pharma NAMS Stock Holding History

Artia Global Partners’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$17.1M	Hold	503,936	–	–	3.15%	10
2026 Q1	$16.1M	Hold	503,936	–	–	3.23%	8
2025 Q4	$17.7M	Buy	503,936 +309,098	+159%	+$11.2M	2.5%	11
2025 Q3	$5.54M	Buy	194,838 +167,519	+613%	+$4.02M	0.88%	19
2025 Q2	$495K	Buy	+27,319	New	+$498K	0.12%	35
2025 Q1	–	Sell	-54,285	Closed	-$1.4M	–	41
2024 Q4	$1.4M	Hold	54,285	–	–	0.5%	30
2024 Q3	$901K	Hold	54,285	–	–	0.25%	38
2024 Q2	$1.04M	Hold	54,285	–	–	0.2%	34
2024 Q1	$1.28M	Buy	+54,285	New	+$1.1M	0.26%	35

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Artia Global Partners's NAMS Position: Q2 2026 in Review

Artia Global Partners held its NewAmsterdam Pharma (NAMS) position steady in Q2 2026 at 503,936 shares worth $17.1M. The position accounts for 3.15% of the portfolio, ranked #10.

Artia Global Partners first reported a position in NAMS in Q1 2024 and has held it in 9 quarters since. The position peaked at $17.7M in Q4 2025. 195 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Artia Global Partners held 503,936 shares of NewAmsterdam Pharma worth $17.1M as of Q2 2026.
Artia Global Partners left its NewAmsterdam Pharma share count unchanged in Q2 2026.
NewAmsterdam Pharma made up 3.15% of Artia Global Partners's portfolio in Q2 2026, its #10 holding.
Artia Global Partners first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 9 quarters since.
Artia Global Partners's NewAmsterdam Pharma position peaked at $17.7M in Q4 2025.
195 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.